D-0278-2019 Class II Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0278-2019 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Oct 19, 2018 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing. The recall status is terminated (terminated Nov 3, 2020).

Recall Details

Product Type
Drugs
Report Date
Nov 21, 2018
Initiation Date
Oct 19, 2018
Termination Date
Nov 3, 2020
Voluntary/Mandated
Voluntary: Firm initiated

Product Description

children's allergy relief (cetirizine hydrochloride) oral solution, 1 mg/mL, Dye Free, Sugar Free, Alcohol Free, 4 FL OZ (120 mL) bottle, Distributed by Rite-Aid, 30 Hunter Lane, Camp Hill, PA 17011, Made in Israel, UPC 0 11822 57363 4.

Reason for Recall

Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

Distribution Pattern

Nationwide in the USA

Code Information

Lot # 313344, Exp 12/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0278-2019
openFDA file date
Oct 21, 2026
Loaded by RegDataLab
Oct 23, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.